Eleclazine, a new selective cardiac late sodium current inhibitor, confers concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in an intact porcine model
- PMID: 27108587
- DOI: 10.1016/j.hrthm.2016.04.015
Eleclazine, a new selective cardiac late sodium current inhibitor, confers concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in an intact porcine model
Abstract
Background: The cardiac late sodium current (INa) has been increasingly implicated in the initiation of atrial fibrillation (AF). Eleclazine (formerly known as GS-6615) is a new selective late INa inhibitor and is undergoing clinical testing for the treatment of cardiac arrhythmias.
Objective: We tested whether late INa inhibition by eleclazine confers protection against atrial premature beats (APBs) and AF.
Methods: In closed-chest anesthetized Yorkshire pigs, epinephrine (2.0 µg/kg, intravenous, bolus over 1 minute) was administered alone to induce APBs (n = 6) or in combination with intrapericardial acetylcholine (0.5-4 mL of 12.5 mM solution) to induce spontaneous AF (n = 11). Effects of eleclazine (0.3 and 0.9 mg/kg, intravenous, over 15 minutes) on APBs and AF were determined.
Results: Epinephrine-induced APBs were reduced >3-fold (P < .04) after eleclazine (0.9 mg/kg) infusion. The combined administration of epinephrine and acetylcholine resulted in AF in all animals tested, which was invariably preceded by APBs. Eleclazine pretreatment suppressed AF in all 7 animals in at least 1 test episode during the 60- to 150-minute observation period (P = .04). The plasma eleclazine level at 120 minutes was 828 ± 45.8 nM, within exposure range evaluated clinically. Eleclazine shortened ventricular QT and atrial PTa intervals by 7% (P < .001 for both) and reduced atrial repolarization alternans (P = .003) and heterogeneity (P = .021) without attenuation of the inotropic response to catecholamine (P = .56). The drug inhibited the enhanced late INa of single atrial myocytes with a potency of 736 ± 67 nM.
Conclusion: Selective cardiac late INa inhibition with eleclazine suppresses autonomically mediated atrial repolarization alternans and heterogeneity, APBs, and AF in an intact porcine model.
Keywords: Acetylcholine; Alternans; Atrial fibrillation; Atrial premature beats; Epinephrine; Heterogeneity; Late sodium current; Repolarization.
Copyright © 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Inhibition of the cardiac late sodium current with eleclazine protects against ischemia-induced vulnerability to atrial fibrillation and reduces atrial and ventricular repolarization abnormalities in the absence and presence of concurrent adrenergic stimulation.Heart Rhythm. 2016 Sep;13(9):1860-7. doi: 10.1016/j.hrthm.2016.06.020. Epub 2016 Jun 16. Heart Rhythm. 2016. PMID: 27317981
-
Eleclazine, an inhibitor of the cardiac late sodium current, is superior to flecainide in suppressing catecholamine-induced ventricular tachycardia and T-wave alternans in an intact porcine model.Heart Rhythm. 2017 Mar;14(3):448-454. doi: 10.1016/j.hrthm.2016.10.021. Epub 2016 Oct 21. Heart Rhythm. 2017. PMID: 27777148
-
The Selective Cardiac Late Sodium Current Inhibitor GS-458967 Suppresses Autonomically Triggered Atrial Fibrillation in an Intact Porcine Model.J Cardiovasc Electrophysiol. 2015 Dec;26(12):1364-9. doi: 10.1111/jce.12824. Epub 2015 Oct 30. J Cardiovasc Electrophysiol. 2015. PMID: 26331943
-
Calcium handling and atrial fibrillation.Wien Med Wochenschr. 2012 Jul;162(13-14):287-91. doi: 10.1007/s10354-012-0109-9. Wien Med Wochenschr. 2012. PMID: 22695810 Review.
-
Late INa Inhibition as an Antiarrhythmic Strategy.J Cardiovasc Pharmacol. 2017 Sep;70(3):159-167. doi: 10.1097/FJC.0000000000000510. J Cardiovasc Pharmacol. 2017. PMID: 28654510 Review.
Cited by
-
Suppression of ventricular arrhythmias by targeting late L-type Ca2+ current.J Gen Physiol. 2021 Dec 6;153(12):e202012584. doi: 10.1085/jgp.202012584. Epub 2021 Oct 26. J Gen Physiol. 2021. PMID: 34698805 Free PMC article.
-
Electrocardiographic intervals associated with incident atrial fibrillation: Dissecting the QT interval.Heart Rhythm. 2017 May;14(5):654-660. doi: 10.1016/j.hrthm.2017.02.005. Epub 2017 Feb 9. Heart Rhythm. 2017. PMID: 28189824 Free PMC article.
-
Inhibition of voltage-gated Na+ currents by eleclazine in rat atrial and ventricular myocytes.Heart Rhythm O2. 2020 Aug;1(3):206-214. doi: 10.1016/j.hroo.2020.05.006. Heart Rhythm O2. 2020. PMID: 32864638 Free PMC article.
-
Eleclazine Suppresses Ventricular Fibrillation in Failing Rabbit Hearts with Ischemia-Reperfusion Injury Undergoing Therapeutic Hypothermia.Pharmacology. 2025;110(3):151-164. doi: 10.1159/000542292. Epub 2024 Oct 28. Pharmacology. 2025. PMID: 39467530 Free PMC article.
-
Understanding AF Mechanisms Through Computational Modelling and Simulations.Arrhythm Electrophysiol Rev. 2019 Jul;8(3):210-219. doi: 10.15420/aer.2019.28.2. Arrhythm Electrophysiol Rev. 2019. PMID: 31463059 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical